The Phase II open label clinical trial—the European arm of which was led by UCL researchers—found that patients who were otherwise facingIn September last year, data from the FOENIX-CCA2 trial led to the US Food and Drug Administration to approve futibatinib, although the UK's National Institute for Clinical Excellence has yet to consider the drug.
When the patients were treated with futibatinib , the results were striking. The drug was more effective at reducing the size of the tumor, with the cancer shrinking by over 40%, compared to 25% with chemotherapy. The drug also produced modest side effects compared to chemotherapy. alongside the cancer, we can offer a personalized treatment that just targets a specific alteration within the cancer.bile duct cancer
Trials are already underway looking at the possibility of using FGFR2 inhibitors as a first line treatment in place of chemotherapy. Bile duct cancer is a rare but aggressive disease in which malignant cells form in the bile ducts; a network of tubes, which connect the liver, gallbladder, and small intestine.